ReviewiMetaOmics2025
Microbiota-gut-brain axis multi-organ chip construction and applications in drug evaluation.
Review in iMetaOmics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The theoretical framework of the microbiota-gut-brain axis (MGBA) elucidates the influence of gut microbiota (GM) on the central nervous system (CNS) and offers novel approaches for diagnosing and treating neurological disorders. The application of microfluidic organ chips to study this axis represents an innovative methodology, enabling multidisciplinary assessment of drug effects. Bionic microphysiological systems based on these chips establish a groundbreaking paradigm for analyzing cross-organ interaction mechanisms within the MGBA. This technology facilitates systematic evaluation of pharmacokinetics, host-microbe coevolution, and neuroendocrine regulation, thereby supporting multimodal cross-validation in pharmacodynamics, toxicology, and translational medicine. This review summarizes the conceptual foundation and mechanistic insights of the MGBA, highlights recent advances in its constituent Multiorgan components, including gut-on-a-chip, blood-brain barrier-on-a-chip, and brain-on-a-chip models, alongside multiorgan chip cascade technologies, and underscores their applications in drug evaluation. Additionally, it discusses future challenges and developmental directions for the MGBA multiorgan chip technologies in this field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.